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Abstract
Background: Intensity-modulated radiation therapy (IMRT) affords unparalleled capacity to
deliver conformal radiation doses to tumors in the central nervous system. However, to date,
there are few reported outcomes from using IMRT, either alone or as a boost technique, for
standard fractionation radiotherapy for glioblastoma multiforme (GBM).
Methods: Forty-two patients were treated with IMRT alone (72%) or as a boost (28%) after 3-
dimensional conformal radiation therapy (3D-CRT). Thirty-three patients with primary disease and
9 patients with recurrent tumors were included. Thirty-four patients (81%) had surgery, with gross
tumor resection in 13 patients (36%); 22 patients (53%) received chemo-radiotherapy. The median
total radiation dose for all patients was 60 Gy with a range from 30.6 to 74 Gy. Standard fractions
of 1.8 Gy/day to 2.0 Gy/day were utilized.
Results: Median survival was 8.7 months, with 37 patients (88%) deceased at last contact.
Nonparametric analysis showed no survival difference in IMRT-boost vs. IMRT-only groups.
Conclusion: While technically feasible, preliminary results suggest delivering standard radiation
doses by IMRT did not improve survival outcomes in this series compared to historical controls.
In light of this lack of a survival benefit and the costs associated with use of IMRT, future prospective
trials are needed to evaluate non-survival endpoints such as quality of life and functional
preservation. Short of such evidence, the use of IMRT for treatment of GBM needs to be carefully
rationalized.
Background
Malignant gliomas represent the most common primary
brain tumors in adults, with approximately 75% of all gli-
omas classified as high-grade tumors. Within high-grade
gliomas, Grade IV gliomas, or glioblastoma multiforme
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median survival prognosis of 8 to 14 months [1-3].
The standard treatment of GBM includes surgical extirpa-
tion, followed by standard fractionation external beam
radiation therapy [4]. When surgical resection is not feasi-
ble, radiation therapy is the primary treatment. Within the
past decades several studies have explored new treatment
regimens for GBM, mainly considering different combina-
tions and doses of chemotherapeutic agents as well as var-
ious radiation therapy dose schema and delivery
techniques [5-8].
Recently, novel radiation approaches affording increased
dose-target conformality, such as intensity-modulated
radiation therapy (IMRT), have been introduced. While
IMRT may afford target isodose coverage superior to other
external beam photon radiation techniques in scenarios
involving geometrically complex target volumes adjacent
to radiosensitive tissues, planning and delivery are
resource intensive and require specific and costly software
and hardware. As of today, the clinical feasibility and util-
ity of IMRT techniques in GBM has not yet been fully elu-
cidated. Also potential outcome benefits of this relatively
novel delivery concept have not been assessed. This
hypothesis generating retrospective study reports survival
endpoint parameters of a consecutive series of patients
with pathologically diagnosed GBM, treated with conven-
tionally fractionated IMRT, delivered either as a mono-
therapy regimen or as a boost following conventional 3D-
CRT.
Methods
Chart review, data collection and analysis were approved
by the Institutional Review Board of The University of
Texas Health Science Center at San Antonio (IRB protocol
# E-054-0242). Inclusion criteria for this retrospective
chart review were pathological diagnosis of glioblastoma
multiforme (WHO Grade IV) treated with IMRT using
daily fractions between 1.8–2 Gy.
Patient characteristics
Between January 1996 and January 2006, 42 patients with
a pathological diagnosis of GBM completed a course of
external beam radiotherapy (EBRT) either utilizing IMRT
for the entire treatment course or as a boost following 3D-
CRT. Of 42 patients, 30 (72%) received the entire treat-
ment course by IMRT. Twelve patients (28%) were treated
by IMRT delivered as a boost following three-dimensional
conformal radiation therapy (3D-CRT). Thirty-three
patients with primary disease and 9 patients with recur-
rent tumors were included in the study. All recurrent
patients previously received radiotherapy, to a median
dose of 52 Gy (range 36–62 Gy) at other institutions. For
details on patient demographics please refer to Table 1.
Radiation therapy simulation and target volume definition
Simulation was performed using a clinical CT simulator
with helical image acquisition technique. For simulation,
all patients were immobilized using a commercially avail-
able thermoplastic mask system (Raycast©-HP, Orfit
Industries, Wijnegem, Belgium). Intra-venous contrast
media was administered unless clinically contraindicated.
CT image data were reconstructed in 2.5 or 3 mm slice
thickness and co-registered with available MR image data
in T2 or FLAIR (fluid attenuation inversion recovery) and
T1 post-contrast weighting.
The initial clinical target volume (CTV) was defined as the
hyper-intensity zone representing tumor and peri-
tumoral edema plus margins of 2 cm on T2-weighted or
FLAIR MR imaging. The target volume for the IMRT boost
(CTVboost) included the contrast-enhancing region on T1-
weighted MRI scans plus a margin of 10 mm. Also, organs
at risk, such as the eyes, optic nerves, optic chiasm, and
brainstem were delineated. CTV and CTVboost volumes
were expanded into planning target volumes by adding 3-
dimensional margins of 2 to 3 mm, values derived from
an assessment of the immobilization accuracy of the
aforementioned mask system [9].
Treatment planning
The techniques employed for 3D-CRT varied slightly with
each prescription. The predominant method of 3D-CRT
delivery was a three-field technique (anterior-posterior
and posterior-anterior field arrangement with a lateral
oblique field) using 6 MV photons with custom blocking.
For inverse IMRT planning, the image datasets were trans-
ferred to the Corvus treatment planning system (Nomos
Corp., Cranberry Township, PA). Inverse IMRT treatment
planning requires the numerical entry of plan parameters
into software templates. At a minimum, the target dose
goal (prescribed dose, PD), the percentage of the target
volume allowed to receive a lower dose (typically 5% or
less), the minimum dose (95% of the PD) and the maxi-
mum dose (typically 107% of PD) desired for the target
volume are entered. Similarly, a template for dose allow-
ances and restrictions for organs at risk is populated. Dose
prescription for the initial target volume was typically 45
to 46 Gy, with an additional dose of 14 or 14.4 Gy for the
boost (total treatment dose of 59.4 or 60 Gy, in daily
doses of 1.8 or 2 Gy).
The serial tomotherapy mode utilized for IMRT delivery in
the present series treats the tumor in a rotational, slice-by-
slice technique. Thus, the angle of rotation about the
patients head (couch angle) and the range of rotation for
each rotational arc were defined. In all cases presented
here, the treatment was delivered as either a single arc, or
with 2 couch angles, typically in a perpendicular arrange-Page 2 of 7
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nates). The rotational arc was typically 340 degrees for the
180 degree couch and a shorter 210 degree arc for the 270
couch angle, to avoid collision with couch or patient.
The utilized binary multi-leaf collimator (MIMiC, Nomos
Corp., Cranberry Township, PA) allows use of two generic
pencil beam dimensions. All initial IMRT plans were com-
puted using the so-called "2 cm" pencil mode (pencil
beam dimension 17 × 10 mm); boost volumes were
mostly treated using the smaller "1 cm" pencil beam
mode (8.5 × 10 mm aperture). Treatment plans were opti-
mized using a simulated annealing algorithm. All IMRT
treatments were delivered using a 6 MV linear accelerator
and the attached MIMiC binary multi-leaf collimator.
Dose prescription
The median prescribed and delivered total dose for all
patients was 60 Gy with a range from 30.6 to 74 Gy. Pri-
mary and recurrent tumors received a median total dose of
60 Gy, although the ranges differed slightly (56–74 Gy for
primary disease, 30.6–74 Gy for recurrent tumors). The
median total dose delivered by IMRT monotherapy was
60 Gy (range 30.6–72 Gy). The median total dose in
patients receiving IMRT as a boost was 66.6 Gy (range 56–
74 Gy). Standard fractions of 1.8 Gy to 2.0 Gy/day were
utilized.
Follow-up
Follow-up evaluations were performed 6 weeks after com-
pletion of therapy and every 3 months thereafter. No
patient was lost to follow up.
Data analysis
Collected data regarding clinical, treatment, and survival
parameters were analyzed using JMP statistical software
(SAS Institute, Cary, NC). Kaplan-Meier survival analysis
was performed using survival data. Non-parametric statis-
tical techniques were utilized for comparative analysis, as
dictated by group size and non-Gaussian distributions.
Results
Of 42 patients, 37 (88%) were deceased at last contact,
with a median survival of 8.7 months (range 1.6–34.7
Table 1: Patient demographic and treatment characteristics; percentiles are listed parenthetically.
Characteristic Series Primary disease Recurrent disease
(n = 42) (n = 33) (n = 9)
Age (yrs)
Median 60 63 46
Range 20–86 40–86 20–59
Sex
Male 27 (64) 20 (60) 7 (78)




8 (19) 6 (19) 2 (22)
Debulking/
resection
34 (81) 27 (81) 7 (78)
Complete 
resection
13(31) 10 (30) 3 (33)
Partial resection 21(50) 17 (51) 4 (44)
Chemotherapy None 19 (45) 17 (51) 2 (22)
Any agent 23 (55) 16 (49) 7 (78)
Carmustine (iv) 5 (12) 2 (6) 3 (33)
Carmustine 
(wafer)
2 (5) 1 (3) 1 (11)
Lomustine 1 (2) 1 (3) -
Irinotecan 3(7) 2 (6) 1 (11)
Penicillamine 3 (7) 3 (9) -
Temozolomide 9(21) 7 (21) 2 (22)
IMRT technique
IMRT Only 30 (72) 22 (66) 8 (89)
3DCRT + IMRT 
boost
12 (28) 11 (33) 1 (11)Page 3 of 7
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radiation therapy for recurrent GBM was 4.5 months
(range 1–16.2, Figure 2). No survival differential was
detected between cohorts receiving 3D-CRT with IMRT-
boost or IMRT as monotherapy (logrank and Wilcoxon
analysis). Wilcoxon and Kruskal-Wallis nonparametric
analysis of correlation between total dose delivered, and
proportion of therapy delivered with IMRT revealed no
detectable difference in survival between IMRT-boost and
IMRT-only groups (Figure 3). Progression-free survival
was calculated as time from diagnosis to either radiologic
progression or demise. A median progression free survival
period of 7.2 months (range 1.0–34.7) was observed for
the entire series, with median time to progression from
diagnosis of 7.3 months for patients with primary disease
compared to a median PFS of 4.5 months in recurrent
GBM patients (p = 0.2, non-significant).
Maximum acute treatment-attributable toxicity, by RTOG
Acute Toxicity Score is listed in Table 2. Five patients
(12%) exhibited greater than RTOG Grade 2 treatment-
related toxicity, specifically acute hemiplegia in 3 patients
requiring hospitalization, and seizure requiring hospital
admission in 2 patients. In no case was therapy aborted
prematurely secondary to acute toxicity attributable to
therapy.
Discussion
While multimodality therapy has been demonstrated to
improve overall survival of patients diagnosed with gliob-
lastoma multiforme compared to surgery alone[4], there
is no established schema that has proven optimal for
treatment of GBM. GBM is notoriously refractory to ther-
apy, with survival rarely exceeding 2 years. More than 95%
of patients with primary GBM receiving an initial therapy
of surgery and external beam radiotherapy(EBRT) with or
without concomitant and/or adjuvant chemotherapy, fail
within 5 years, and recent literature suggests that even this
slim margin of survival may be exaggerated[10].
Several studies have concluded that local tumor progres-
sion was the predominant pattern of failure [11-13]. The
observation that the vast majority of recurrences are focal,
at the initial site of the neoplasm[14], has provided an
impetus for dose delivery to reduced radiotherapy vol-
umes. Subsequent technological advances in external
beam radiation therapy have resulted in investigation into
more tumor-conformal radiation delivery techniques,
such as 3D-CRT. These techniques spare normal brain tis-
sue from the high-dose area of radiation and can theoret-
ically afford higher radiation dose delivery to brain
tumors safely. In an effort to explore dose escalation with
3D-CRT, Nakagawa et al. studied survival in GBM patients
using multi-leaf collimator conformal radiation ther-
apy[1]. Approximately 55% of the patients were treated to
a dose of 60 to 80 Gy and 44% were treated to 90 Gy in
addition to intravenous chemotherapy, which resulted in
an alteration of patterns of failure, but no discernable sur-
vival benefit.
The inception of IMRT brought with it great optimism
with regard to brain tumors, as the radiation dose confor-
mality available with IMRT is unparalleled[15,16]. How-
ever, since the development of IMRT in the 1990s, few
studies in the literature have assessed the survival impact
of this radiotherapy modality with regard to GBM. In a
Survival from inception of radiotherapy for primary (solid line) and ecurrent (dashed line) diseaseFigure 2
Survival from inception of radiotherapy for primary (solid 
line) and recurrent (dashed line) disease.
Kaplan-Meier overall survival for all 42 patients (+ = alive at last contact, x = deceased)Figure 1
Kaplan-Meier overall survival for all 42 patients (+ = alive at 
last contact, x = deceased).Page 4 of 7
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cases out of a total of 58 high grade gliomas treated with
standard fractionation IMRT at Memorial Sloan-Kettering
Cancer Center[17]. This series exhibited exceedingly simi-
lar results to the current series, with reported overall sur-
vival of 9 months for glioblastoma. While the Memorial
group used dynamic leaf IMRT, in contrast to serial tomo-
therapeutic IMRT utilized in the present series, we believe
that the nearly equivalent results from both series, in sim-
ilar numbers of patients, treated with similar dose param-
eters, add confirmation to the findings reported here.
The majority of other reports of GBM treated with IMRT
involve altered fractionation schedules, with the intent of
using the amenity of IMRT dose shaping to minimize
adjacent tissue dose while maximizing radiobiological
parameters in an effort to improve tumor dose in primary
tumors. However, the results from such series have failed
expectations with regard to added survival. Thilmann et
al[18] examined the feasibility and safety of an integrated
IMRT boost in addition to conventional EBRT in 20
patients, and, though survival data is not yet available, a
Phase III trial is underway. Suzuki et al [19] also studied
the feasibility of an integrated boost method using inten-
sity modulated radiotherapy (IMRT). The total dose deliv-
ered was 70 Gy in 28 fractions of 2.5 Gy. No delay in
therapy from radiation toxicity was necessitated in any of
the 6 enrolled patients. Sultanem et al[20] recently pub-
lished data from a series of 25 patients treated with hypof-
ractionated IMRT (60 Gy in 3 Gy increments). Median
survival in said study was 9.5 months, consonant with the
survival observed in the present study.
In addition to individuals with primary disease, the con-
formal dosimetric profiles attainable with IMRT have
been examined as a means of treating recurrent GBM.
Voynov et al[21] record a series of 10 patients for whom
stereotactic IMRT using serial tomotherapy was imple-
mented in an effort to treat recurrent malignant gliomas,
resulting in a median overall survival time of 10 months,
and 50% and 33.3% one and two year survival, respec-
tively. The data derived from the present series reveals
slightly inferior outcomes for recurrent disease, with
median survival of <5 months.
To our knowledge, this dataset represents one of the few
extant series of GBM patients treated with standard frac-
tionation IMRT alone, as well as the largest retrospective
study to date of survival data with a 3D-CRT/IMRT boost
technique. Our study revealed no substantial differential
in survival times of patients treated with IMRT conformal
techniques from reported survival in the literature of
patients treated with conventional methods, and is simi-
lar to recent studies exploring alternative fractionation
IMRT methodologies [18-20]. There are several possible
explanations for this observation. Admittedly, this review
is retrospective and numerically limited, with several het-
erogenous treatment schemas. Additionally, dose escala-
tion was not a primary focus of treatment regimens within
this series, nor was fraction-size optimization. These cave-
ats draw attention to the necessity of standardized trials
designed to optimize the dosage and fractionation sched-
ules utilized in the treatment of GBM. Additionally, while
survival was the primary end-point of note in this study,
definitive explication of the role of conformal techniques
in non-mortality endpoints, such as disease progression,
Survival for patients treated with IMRT alone (solid line) or 3D-CRT with IMRT boost (dashed line)Figure 3
Survival for patients treated with IMRT alone (solid line) or 
3D-CRT with IMRT boost (dashed line).
Table 2: RTOG Maximum acute toxicity score by cohort; percentiles are listed parenthetically.
Maximum RTOG Acute Toxicty Series Primary disease Recurrent disease IMRT 3DCRT+IMRT boost
0 6(14) 6 (18) 0 (0) 5 (16) 1 (8)
1 11 (26) 9 (27) 2 (22) 6 (20) 5 (42)
2 20 (48) 14 (42) 6 (67) 15 (50) 5 (42)
3 5 (12) 4 (12) 1 (11) 4 (13) 1 (8)Page 5 of 7
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nitive outcomes, toxicity reduction and/or quality of life
enhancement must be explored as they may represent a
more realistic aim in IMRT-based interventions than
extension of mortality[22,23].
Nonetheless, the preliminary results of our analysis sug-
gest that undue optimism regarding reduction in mortal-
ity for GBM treated with IMRT therapies must be
tempered by the recalcitrance of this tumor to radiother-
apy. No extant IMRT series to date has matched the sur-
vival outcomes observed in the control arm of the EORTC
trial[24], where a 12.1 month median survival using 60
Gy in 2 Gy fractions delivered using quality-assured 3D-
CRT was achieved. Consequently, it remains to be seen
whether the addition of IMRT will improve upon the
impressive 14.6 month median survival seen in the same
study's experimental arm of 3D-CRT plus concurrent
temozolomide.
Conclusion
Conscientious practice requires justification for a tech-
nique which is markedly more complicated and econom-
ically costly, and has not, at present, demonstrated
conferral of a statistical survival greatly distinct from con-
ventional series. If, as our data suggests, standard fraction-
ation IMRT does not provide an imminent and effective
benefit in terms of mortality, careful thought must be
made to widespread initiation of treatment protocols
whose dollar costs are several times that of conventional
techniques, with questionable therapeutic advan-
tages[17]. It is our belief that elucidation of the potential
role of IMRT and other conformal therapies is best accom-
plished through standardized clinical trials and multi-
institutional cooperative group studies, exploration of




intensity modulated radiation therapy (IMRT)
three-dimensional conformal radiation therapy (3D-CRT)
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